[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1993515T3 - Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme - Google Patents

Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme

Info

Publication number
DK1993515T3
DK1993515T3 DK07710794T DK07710794T DK1993515T3 DK 1993515 T3 DK1993515 T3 DK 1993515T3 DK 07710794 T DK07710794 T DK 07710794T DK 07710794 T DK07710794 T DK 07710794T DK 1993515 T3 DK1993515 T3 DK 1993515T3
Authority
DK
Denmark
Prior art keywords
same
poloxamer
solubilizing
dispersing
application
Prior art date
Application number
DK07710794T
Other languages
English (en)
Inventor
Hanspeter Strobel
Original Assignee
Laboswiss Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboswiss Ag filed Critical Laboswiss Ag
Application granted granted Critical
Publication of DK1993515T3 publication Critical patent/DK1993515T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A61K8/988—Honey; Royal jelly, Propolis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Animal Husbandry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
DK07710794T 2006-03-10 2007-03-09 Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme DK1993515T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3772006 2006-03-10
PCT/CH2007/000131 WO2007104173A2 (de) 2006-03-10 2007-03-09 Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben

Publications (1)

Publication Number Publication Date
DK1993515T3 true DK1993515T3 (da) 2009-12-07

Family

ID=38137765

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07710794T DK1993515T3 (da) 2006-03-10 2007-03-09 Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme

Country Status (17)

Country Link
US (2) US8703195B2 (da)
EP (1) EP1993515B1 (da)
JP (2) JP5678359B2 (da)
KR (1) KR101433962B1 (da)
CN (1) CN101400337A (da)
AT (1) ATE437627T1 (da)
AU (1) AU2007224940B2 (da)
BR (1) BRPI0708773B1 (da)
CA (1) CA2643389C (da)
DE (1) DE502007001190D1 (da)
DK (1) DK1993515T3 (da)
EA (1) EA026670B1 (da)
ES (1) ES2330898T3 (da)
HR (1) HRP20090573T1 (da)
PL (1) PL1993515T3 (da)
PT (1) PT1993515E (da)
WO (1) WO2007104173A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043439A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009033739A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2187913B1 (en) 2007-09-11 2012-07-11 Mondobiotech Laboratories AG Ac-RFMWMR-NH2 for use in the treatment of Mycobacterium tuberculosis related diseases
CA2699006A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008306257A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of RFRP, alone or in combination with neurokinin-B, as a therapeutic agent
AU2008297893A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a deslorelin and mastoparan as a therapeutic agent
KR20100056523A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｇｒｆ-1 (1-29) 및 코르티코트로핀-방출 인자의 용도
RU2010114023A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114048A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида дефензина в качестве терапевтического средства
US20100204151A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009033803A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents
EP2274053A2 (en) 2007-09-11 2011-01-19 Mondobiotech Laboratories AG Use of the human pancreatic polypeptide as a therapeutic agent
EP2187956A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a laminin peptide as a therapeutic agent
KR20100059860A (ko) 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 Ｈｂｖ 감염 치료시 치료제로서의 ｎｆ―카파ｂ 저해제 ｓｎ５０ 및 임의의 안지오텐신 ⅲ의 용도
KR101829201B1 (ko) 2009-05-11 2018-02-19 베르그 엘엘씨 외대사 변환인자, 다차원 세포내 분자 또는 환경 영향인자를 사용하여 종양성 장애를 치료하는 방법
EP2359702B1 (en) 2010-01-22 2014-06-04 Symrise AG Solubilization agent for solubilizing polyphenols, flavonoids and/or diterpenoid glucosides
SG10201501872XA (en) * 2010-03-12 2015-05-28 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP2390284B2 (en) 2010-05-28 2017-03-15 Omya International AG Process for manufacturing high solids suspensions of mineral materials
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
AU2012271274B2 (en) 2011-06-17 2017-07-27 Berg Llc Inhalable pharmaceutical compositions
JP5869856B2 (ja) * 2011-11-30 2016-02-24 キユーピー株式会社 容器入り大根おろし含有液状調味料
BRPI1106762A2 (pt) * 2011-12-22 2013-11-05 Bioactive Biomateriais Ltda Composição polimérica contendo bioativos naturais aplicáveis em formulações farmacêuticas e cosméticas
KR101451401B1 (ko) * 2012-12-14 2014-10-22 주식회사 휴메딕스 비타민 c와 비타민 e의 컨쥬게이트 및 그를 포함하는 항산화제
JP6122646B2 (ja) * 2013-01-23 2017-04-26 昭和電工株式会社 皮膚外用剤
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
US20160074517A1 (en) * 2013-05-06 2016-03-17 Basf Se Aqueous formulations of sparingly water-soluble active ingredients comprising as solubilizer a mixture of poloxamers differing in hydrophobicity
JP6232807B2 (ja) * 2013-07-30 2017-11-22 ユーハ味覚糖株式会社 グミキャンディ
CA2923216A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
EP3216443A1 (en) 2016-03-10 2017-09-13 Athenion AG Beverage preparation capsule for delivery of a solubilisate
EP3388054A1 (en) 2017-04-12 2018-10-17 Athenion AG Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
CN108271814A (zh) * 2018-01-21 2018-07-13 王小凤 一种糖尿病患者可食用的苹果的培育剂及其制备方法
CN108210360B (zh) * 2018-02-06 2021-02-12 德之馨（上海）有限公司 一种水溶性美白配方及其制备方法和用途
TWI818102B (zh) * 2018-10-24 2023-10-11 瑞士商先正達合夥公司 新的阿巴美丁可溶性濃縮物組成物(sl)
WO2020250242A1 (en) * 2019-06-10 2020-12-17 Godrej Agrovet Limited Bud break formulation
JP7504589B2 (ja) * 2019-12-27 2024-06-24 ポーラ化成工業株式会社 透明な可溶化組成物
EP3909564A1 (de) 2020-05-12 2021-11-17 Metabolic Tuning AG Feste lösung aus gummi arabicum und wenigstens einem fettlöslichen wirkstoff
KR102365402B1 (ko) * 2021-05-31 2022-02-18 김상태 사포닌을 함유한 깻잎 및 이의 생산방법
CN115096678A (zh) * 2022-06-21 2022-09-23 杭州师范大学 一种基于聚乙二醇辅助机械无定形分散的植物中蒽醌类化合物的提取方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953496A (en) * 1958-12-02 1960-09-20 Upjohn Co Vitamin emulsion
CA1088427A (en) * 1975-12-22 1980-10-28 Andrew W. Finkstein Imidazoline-containing hair shampoo compositions
JPS5660565A (en) * 1979-10-22 1981-05-25 Dainichiseika Color Chem Composition for deodorizing aromatic
US4383987A (en) * 1981-06-26 1983-05-17 Colgate/Palmolive Company Foaming dentifrice containing nonionic surface active agent
GB2181737A (en) * 1985-08-29 1987-04-29 Avent Medical Ltd Liquid shampoo composition
US4810503A (en) * 1987-03-31 1989-03-07 Basf Corporation Polymers which form gels at low concentrations in water
ZA95519B (en) * 1994-02-07 1995-09-28 Isk Biotech Corp Pesticidal micronutrient com psitions containing zinc oxide
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6193954B1 (en) * 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US6027716A (en) * 1997-04-02 2000-02-22 Farmo-Nat Ltd. Synergistic herbal extracts
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
US6197305B1 (en) * 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
AUPP915099A0 (en) * 1999-03-12 1999-04-15 Monk, Michael Mendel Improved composition for oral administration
WO2000071163A1 (en) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6503955B1 (en) * 1999-09-11 2003-01-07 The Procter & Gamble Company Pourable liquid vehicles
NL1014778C1 (nl) * 2000-03-29 2001-10-02 Giorgio Panin Een detergent samenstelling voor persoonlijke hygiÙne met een hoge inhoud aan vitamine E of derivaten daarvan.
DE10343872A1 (de) * 2003-09-23 2005-04-21 Bayer Cropscience Ag Suspensionskonzentrate
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol

Also Published As

Publication number Publication date
JP2009531305A (ja) 2009-09-03
EP1993515B1 (de) 2009-07-29
EA026670B1 (ru) 2017-05-31
PL1993515T3 (pl) 2010-01-29
WO2007104173A3 (de) 2007-11-22
ES2330898T3 (es) 2009-12-16
WO2007104173A2 (de) 2007-09-20
JP2015028028A (ja) 2015-02-12
BRPI0708773B1 (pt) 2021-10-19
AU2007224940B2 (en) 2013-08-29
US8703195B2 (en) 2014-04-22
BRPI0708773A2 (pt) 2011-06-14
US20140193513A1 (en) 2014-07-10
JP5678359B2 (ja) 2015-03-04
KR101433962B1 (ko) 2014-08-25
ATE437627T1 (de) 2009-08-15
AU2007224940A1 (en) 2007-09-20
KR20080108262A (ko) 2008-12-12
US9114167B2 (en) 2015-08-25
CA2643389A1 (en) 2007-09-20
EP1993515A2 (de) 2008-11-26
CN101400337A (zh) 2009-04-01
US20090280987A1 (en) 2009-11-12
DE502007001190D1 (de) 2009-09-10
EA200801850A1 (ru) 2009-06-30
HRP20090573T1 (hr) 2009-11-30
WO2007104173B1 (de) 2008-01-10
CA2643389C (en) 2014-12-02
PT1993515E (pt) 2009-11-05

Similar Documents

Publication Publication Date Title
DK1993515T3 (da) Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme
Sridharan et al. Jammed emulsions with adhesive pea protein particles for elastoplastic edible 3D printed materials
Vaia et al. Solvent-mediated disruption of bovine casein micelles at alkaline pH
ATE435256T1 (de) Verfahren zur herstellung von kationisch stabilisierten und in wasser redispergierbaren polymerpulverzusammensetzungen
BR112012027528A2 (pt) composição agroquímica estabilizada
PA8784701A1 (es) Proceso y dispersión sólida que contiene revaprazan para la preparación del mismo
CO6331351A2 (es) Formulaciones que contienen celulosa bacteriana que carecen de un componente de carboximetilcelulosa.
Desai et al. Critical factors affecting cell encapsulation in superporous hydrogels
CO2018006643A2 (es) Composiciones de polímero líquido referencia cruzada con la solicitud relacionada
WO2009095562A3 (fr) Biomateriau permettant la delivrance controlee d'actifs
WO2006098966A3 (en) Stable mixed emulsions comprising semisolid dispersions of at least two discrete and distinctly different particle size ranges
FR3030227B1 (fr) Emulsion stabilisees par des particules composites amphiphiles
NO20085175L (no) Konisk skrueblander.
DE69906974D1 (de) Thixotrope formulierungen zur befüllung von gelatinekapseln
EA201900446A1 (ru) Композитный материал
AR059452A1 (es) Un solvente no ionico , una composicion farmaceutica estabilizada que comprende un taxano y un proceso para la preparacion del solvente no ionico
MX350026B (es) Materiales polimericos.
BR112013007346A2 (pt) método para misturar ingredientes, dispositivo para a descarga de um material, e, aparelho para misturar um material
DE502007006511D1 (de) Verfahren zur herstellung von mikropartikeln
Tarameshlou et al. A microfluidic approach to synthesize monodisperse poly (2-hydroxyethyl methacrylate) based spherical microgels via water in water emulsion technique
RS51028B (sr) Postupak za solubilizaciju, disperziju i stabilizaciju supstanci, proizvodi proizvedeni po ovom postupku kao i upotreba istih
Al-Neshawy et al. Securing the stable protective pore system of concrete-Report for “Robust Air “
Mesaros et al. Study upon water sorption, solubility and mechanical properties of orthodontic adhesives
Chen et al. Interfacial Dynamics and Environmental Responsiveness of Double Emulsions Stabilized by Zein Particles and Surfactant Using Microfluidic Techniques
LAZĂR et al. Band gaps in 2D photonic crystals with square symmetry